Barr Launches Generic Actiq
When Cephalon acquired Cima Labs for $515 million, the FTC allowed the merger to proceed on the condition that Barr be allowed to compete by producing the same drug.
The Federal Trade Commission approved the agreement in August 2004, but several elements held up the launch.
Barr’s license for...
To view the full article, register now.